Second Sight Medical Products Stock Forecast, Price & News

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Second Sight Medical Products in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Second Sight Medical Products stock.
View analyst ratings for Second Sight Medical Products or view top-rated stocks.

Wall Street analysts have given Second Sight Medical Products a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Second Sight Medical Products wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Second Sight Medical Products saw a decline in short interest in February. As of February 12th, there was short interest totaling 291,900 shares, a decline of 22.6% from the January 28th total of 376,900 shares. Based on an average daily volume of 3,180,000 shares, the short-interest ratio is presently 0.1 days. Approximately 4.7% of the shares of the company are short sold.
View Second Sight Medical Products' Short Interest.

Second Sight Medical Products is scheduled to release its next quarterly earnings announcement on Thursday, March 18th 2021.
View our earnings forecast for Second Sight Medical Products.

Second Sight Medical Products, Inc. (NASDAQ:EYES) issued its quarterly earnings data on Monday, June, 29th. The medical device company reported ($0.57) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.41) by $0.16.
View Second Sight Medical Products' earnings history.

Second Sight Medical Products' stock was trading at $3.53 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, EYES stock has increased by 64.0% and is now trading at $5.79.
View which stocks have been most impacted by COVID-19.

1 brokerages have issued twelve-month price targets for Second Sight Medical Products' stock. Their forecasts range from $2.50 to $2.50. On average, they anticipate Second Sight Medical Products' share price to reach $2.50 in the next twelve months. This suggests that the stock has a possible downside of 56.8%.
View analysts' price targets for Second Sight Medical Products or view top-rated stocks among Wall Street analysts.

5 employees have rated Second Sight Medical Products CEO Will McGuire on Glassdoor.com. Will McGuire has an approval rating of 57% among Second Sight Medical Products' employees. This puts Will McGuire in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

Some companies that are related to Second Sight Medical Products include Zynex (ZYXI), Stereotaxis (STXS), Cutera (CUTR), Edap Tms (EDAP), Soleno Therapeutics (SLNO), FONAR (FONR), BioSig Technologies (BSGM), Electromed (ELMD), electroCore (ECOR), IRIDEX (IRIX), ENDRA Life Sciences (NDRA), Fc Global Realty (FCRE), ReShape Lifesciences (RSLS), Helius Medical Technologies (HSDT) and Precision Optics (PEYE).
View all of EYES's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Second Sight Medical Products investors own include Zynerba Pharmaceuticals (ZYNE), Adaptimmune Therapeutics (ADAP), Cara Therapeutics (CARA), VBI Vaccines (VBIV), Shopify (SHOP), Corbus Pharmaceuticals (CRBP), Sorrento Therapeutics (SRNE), (CGC), Ekso Bionics (EKSO) and OPKO Health (OPK).

(EYES) raised $32 million in an initial public offering (IPO) on Wednesday, November 19th 2014. The company issued 3,500,000 shares at a price of $9.00 per share. MDB Capital Group, LLC served as the underwriter for the IPO.

Second Sight Medical Products trades on the NASDAQ under the ticker symbol "EYES."

Second Sight Medical Products' stock is owned by many different retail and institutional investors. Top institutional shareholders include Renaissance Technologies LLC (0.11%), Jane Street Group LLC (0.09%) and Squarepoint Ops LLC (0.07%). Company insiders that own Second Sight Medical Products stock include Edward David Randolph and Jonathan Will Mcguire.
View institutional ownership trends for Second Sight Medical Products.

EYES stock was acquired by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Jane Street Group LLC, and Squarepoint Ops LLC.
View insider buying and selling activity for Second Sight Medical Products or or view top insider-buying stocks.

Shares of EYES can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of EYES stock can currently be purchased for approximately $5.79.

Second Sight Medical Products has a market capitalization of $133.85 million and generates $3.38 million in revenue each year. The medical device company earns $-33,590,000.00 in net income (profit) each year or ($1.91) on an earnings per share basis.

Second Sight Medical Products employs 12 workers across the globe.

The official website for Second Sight Medical Products is www.secondsight.com.

Second Sight Medical Products is headquartered at 12744 SAN FERNANDO ROAD SUITE 400, SYLMAR CA, 91342.

Second Sight Medical Products' mailing address is 12744 SAN FERNANDO ROAD SUITE 400, SYLMAR CA, 91342. The medical device company can be reached via phone at 818-833-5000 or via email at [email protected]